BDNF / TrkB activators in Parkinson's disease: A new therapeutic strategy
Journal of Cellular and Molecular Medicine · 2024-05 · 28 (10)
DOI: 10.1111/jcmm.18368 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Journal of Cellular and Molecular Medicine, online erschienen am 16.05.2024. Verfasst von Naif H Ali und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, Medical College, Najran University, Najran, Saudi Arabia. Hauptthemen laut MEDLINE: Brain-Derived Neurotrophic Factor, Parkinson Disease, Receptor, trkB, Signal Transduction. Die Arbeit wurde bisher 53-mal zitiert (Crossref) und nennt 194 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: University of Witten-Herdecke Germany.
Abstract (Originalsprache)
Parkinson's disease (PD) is a neurodegenerative disorder of the brain and is manifested by motor and non‐motor symptoms because of degenerative changes in dopaminergic neurons of the substantia nigra. PD neuropathology is associated with mitochondrial dysfunction, oxidative damage and apoptosis. Thus, the modulation of mitochondrial dysfunction, oxidative damage and apoptosis by growth factors could be a novel boulevard in the management of PD. Brain‐derived neurotrophic factor (BDNF) and its receptor tropomyosin receptor kinase type B (TrkB) are chiefly involved in PD neuropathology. BDNF promotes the survival of dopaminergic neurons in the substantia nigra and enhances the functional activity of striatal neurons. Deficiency of the TrkB receptor triggers degeneration of dopaminergic neurons and accumulation of α‐Syn in the substantia nigra. As well, BDNF/TrkB signalling is reduced in the early phase of PD neuropathology. Targeting of BDNF/TrkB signalling by specific activators may attenuate PD neuropathology. Thus, this review aimed to discuss the potential role of BDNF/TrkB activators against PD. In conclusion, BDNF/TrkB signalling is decreased in PD and linked with disease severity and long‐term complications. Activation of BDNF/TrkB by specific activators may attenuate PD neuropathology.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Internal Medicine, Medical College, Najran University, Najran, Saudi Arabia.
- Department of Clinical Pharmacology and Medicine, College of Medicine, Mustansiriyah University, Baghdad, Iraq.
- Head of Jabir ibn Hayyan Medical University, Najaf, Iraq.
- University Centre for Research and Development, Chandigarh University, Mohali, Punjab, India.
- Department of Research and Development, Funogen, Athens, Greece.
- Department of Research and Development, AFNP Med, Wien, Austria.
ORCID-Profile: Athanasios Alexiou, Hebatallah M Saad
Förderung
- University of Witten-Herdecke Germany
Zitieren
APA
Ali, N. H., Al-Kuraishy, H. M., Al-Gareeb, A. I., Alexiou, A., Papadakis, M., AlAseeri, A. A., Alruwaili, M., Saad, H. M., & Batiha, G. E. (2024). BDNF / TrkB activators in Parkinson's disease: A new therapeutic strategy. Journal of Cellular and Molecular Medicine, 28(10). https://doi.org/10.1111/jcmm.18368
Vancouver
Ali NH, Al-Kuraishy HM, Al-Gareeb AI, Alexiou A, Papadakis M, AlAseeri AA, et al. BDNF / TrkB activators in Parkinson's disease: A new therapeutic strategy. Journal of Cellular and Molecular Medicine. 2024;28(10). doi:10.1111/jcmm.18368
BibTeX
@article{Ali2024,
author = {Ali, Naif H and Al-Kuraishy, Hayder M and Al-Gareeb, Ali I and Alexiou, Athanasios and Papadakis, Marios and AlAseeri, Ali Abdullah and Alruwaili, Mubarak and Saad, Hebatallah M and Batiha, Gaber El-Saber},
title = {BDNF / TrkB activators in Parkinson's disease: A new therapeutic strategy},
journal = {Journal of Cellular and Molecular Medicine},
year = {2024},
volume = {28},
number = {10},
doi = {10.1111/jcmm.18368}
}
EUVIMED